Nastech Pharmaceutical has promoted Gordon Brandt to the position of president. He was formerly executive vice president of clinical research and medical affairs.
In his new role, Brandt takes over for former President Steven Quay, who will continue to serve as Nastech’s chairman and CEO.
"This move … allows me to increase my efforts on establishing [spinout] MDRNA as an independent company concentrating on the development of RNA-based therapeutics, which we believe will eventually provide greater focus for both companies,” Quay said in a statement.